…Gantier MP, Gattorno M, Geyer M, Volpi S, DAVIDSON S*, Masters SL*. *Joint authorship (2022) Deficiency in coatomer complex I causes aberrant activation of STING signalling. Nature Communications DAVIDSON S,…… Read more
…present in every life form, including bacteria and viruses, and are essential for our immune system to detect infections. Dr Michael Gantier A study published in Nucleic Acids Research has…… Read more
…and inflammatory diseases, focused on proteins targeting novel molecular pathways,” A/Prof Nold said. Dr Michael Gantier Fielding Innovation Award Dr Gantier trained as a French biological engineer, who completed a…… Read more
…as skin disease exacerbation. What did the researchers discover? Hudson Institute’s Dr Michael Gantier, Research Group Head of the Nucleic Acids and Innate Immunity Research group, led a study published…… Read more
…and inflammatory diseases, focused on proteins targeting novel molecular pathways,” A/Prof Nold said. Dr Michael Gantier Fielding Innovation Award Dr Gantier trained as a French biological engineer, who completed…… Read more
…Fuller PJ and Stowasser M (2018) Is it time to screen all hypertensives for primary aldosteronism? Medical Journal of Australia. Jul 16;209(2):57-59. – co-authored with Prof Michael Stowasser, an international…… Read more
…Monash University Melbourne Australia Associate Professor Morag Young Baker Institute Melbourne Australia Professor Brian Smith La Trobe University Melbourne Australia Professor Michael Stowasser University of Queensland Brisbane Australia Publication highlights…… Read more
An existing cancer drug could potentially modify a severe hyper-inflammatory ‘storm’ associated with some conditions, which may include the COVID-19 virus, according to Hudson Institute researchers. Dr Michael Gantier The…… Read more
…by Dr Michael Gantier, is looking for treatments to help prevent chronic and hyper-acute inflammation. Nucleic acids are the root cause of toxic inflammation in chronic diseases like lupus, or…… Read more
…Michael Gantier The researchers joined forces with cancer drug developer, Noxopharm, and discovered that the oncology company’s prostate cancer medication idronoxil could block the production of several pro-inflammatory proteins, known…… Read more
